MAPT and Alzheimer disease: While cerebrospinal fluid (CSF) measures of amyloid and tau proteins are generally accepted as biomarkers of AD pathology, neuroimaging measures used to indicate white matter alterations throughout the brain remain less widely endorsed as candidate biomarkers.